Legend Biotech to Discuss Third Quarter Results
Legend Biotech Corporation (NASDAQ: LEGN), a leading name in the cell therapy industry, will be hosting an investor conference call aimed at shedding light on its performance for the third quarter of 2025. This call is scheduled to take place at 8:00 AM ET, providing a platform for leaders within the company to present crucial insights and results.
What to Expect During the Conference Call
During the call, participants can anticipate an in-depth analysis of Legend Biotech's activities and achievements for the quarter. Senior executives will discuss key metrics, innovations, and strategies that the company has implemented. They will outline not only the current performance but also how these results align with the company’s long-term goals.
Performance Highlights
As a pioneer in the CAR-T cell therapy arena, Legend Biotech's commitment to revolutionary treatments, such as CARVYKTI, has kept them at the forefront of cancer care. This is a one-time treatment designed specifically for relapsed or refractory multiple myeloma, developed in collaboration with Johnson & Johnson. Insights from the call are expected to reflect on the treatment’s market impact and how it is expanding patient access.
Future Directions
In addition to reviewing the current quarter, the conversation will likely touch on future endeavors and innovations within the company. Legend Biotech is actively working on enhancing its cell therapy modalities and expanding its pipeline of innovative treatments. This focus on growth and development aligns with its vision of transforming cancer treatment.
Accessing the Conference Call
For those interested in following the proceedings, the live audio webcast can easily be accessed via the company’s official website. Attendees are encouraged to join the call to hear directly from the management team about the latest advancements and strategic plans.
Recording Availability
Following the conclusion of the live call, a replay will be available approximately two hours later on the Investor Relations section of Legend Biotech’s website. This ensures that stakeholders have the opportunity to review the discussions at their convenience.
About Legend Biotech
Legend Biotech, boasting over 2,800 employees, stands as the largest standalone cell therapy company around the globe. Its ambitions in the biotechnology industry are firmly rooted in changing the landscape of cancer treatment. The company’s flagship therapeutic product, CARVYKTI, showcases its dedication to providing significant advancements in cancer care, showing promise for multiple myeloma patients.
Commitment to Innovation
The company's strategy to create an end-to-end cell therapy model is driven by the goal of maximizing therapeutic potential and access to its innovative drugs. Legend Biotech’s commitment to fostering research and development across its product pipeline is indicative of its intent to continue being a trailblazer in the field.
Contact Information
Investor Contact:
Jessie Yeung
Tel: (732) 956-8271
Email: jessie.yeung@legendbiotech.com
Press Contact:
Alexandra Ventura
Tel: (732) 850-5598
Email: media@legendbiotech.com
Frequently Asked Questions
What is the purpose of the conference call?
The conference call aims to discuss and review the performance of Legend Biotech during the third quarter of 2025.
Who will be presenting during the call?
Senior leaders from Legend Biotech will be presenting insights and performance metrics during the call.
How can I access the conference call?
Interested parties can join the live audio webcast of the call through the official Legend Biotech website.
When will the call take place?
The investor conference call is scheduled to occur at 8:00 AM ET on the specified date.
Will there be a recording available?
Yes, a replay of the call will be made available on the Investor Relations section of Legend Biotech's website approximately two hours after the live event concludes.
